5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia

OBJECTIVE: To compare the risk of prostate cancer mortality among men treated with 5- alpha reductase inhibitors (5-ARIs) with those treated with alpha-adrenergic blockers (ABs) in community practice settings. PATIENTS AND METHODS: A retrospective matched cohort (N=174,895) and nested case-control s...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mayo Clin Proc
Autores principales: Wallner, Lauren P., DiBello, Julia R., Li, Bonnie H., Van Den Eeden, Stephen K., Weinmann, Sheila, Ritzwoller, Debra P., Abell, Jill E., D’Agostino, Ralph, Loo, Ronald K., Aaronson, David S., Richert-Boe, Kathryn, Horwitz, Ralph I., Jacobsen, Steven J.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8080281/
https://ncbi.nlm.nih.gov/pubmed/28126151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.mayocp.2016.07.023
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares